Replies to post #22198 on Cytodyn Inc (CYDY)

[weasel6667]

Can you estimate a number what the uplisting and short-term costs would be?
One would/ could consider they have all ducks in a row and financing of the uplisting would not be a (or the) problem when they actually announce the Intention of a RS with the following uplisting. Did the financing deal bust in the last minute?

I would like to know if this slow death spiral (Paulson raises) has less risk than a proper prepared uplisting which other companies have also mastered in the past. In the opinion of management it seems so.

[gestalt2]

As tired as I am with the warrant holders selling shares and holding warrants with near zero risk, It is possibly the only way to fund the trials and is the easiest/quickest way also. There are other ways of funding but they take time and are not as easy to manage. Any investor willing to put up real cash to fund the company wants 3 things: ability to manage risk, ability to scale and have the possibility of a payday at any point in the future. If the company put more restrictions in the fund raising they likely would not get the funds at all. The prospect of uplisting for me was a chance to shift the percentage of warrent holders who own stock to have more retail/open market stock holders. This would be good for everyone. However it is not the worst thing in the world to stay in the basement as we are, the cost of being on a large market and the potential for SP volatility is much less. I just think of it as we are class B investors in a company that just happens to have a ticker symbol.

I absolutely hate the current valuation now mostly because it is so far away from where it should be and could be, It makes me wonder if I'm missing something. But I compare it to investing in a friend's new bar, where it is worthless until it generates revenue. I don't blame the warrant holders for being risk managers and I don't blame management for taking the deal. I do have a problem with Management stating that they are working hard to get the SP to rise organically for the past 2 years. That was just ridiculous and makes me wonder how they could think that having a huge majority of shares owned by warrant holders would not keep us in this situation. The whole R/S and uplist screw up bothered me more because it showed that mgmt really does not understand the handling of a stock price and market. Hopefully this won't matter in a B/O situation. Long ago some here were very concerned that the company's mgmnt does not add to the value of the company, but in the B/O that does not matter one bit because anyone buying this is buying the product - not the people. Mgmt's job will be done at that point and all they need to do is not screw it up getting us there. Mgmt staying focused on the trials is really what they should be doing, the cost to complete the trials is so much less than the approved value of pro140, it does not matter much what SP level they raise funds at or what the SP does day to day.